Eli Lilly announces phase III study results of oral small molecule GLP-1 drug

智通財經
2025.06.22 01:54
6 月 21 日，禮來公佈每日一次口服小分子 GLP-1 類藥物 orforglipron 三期研究結果。結果顯示，在所有劑量組中，這款在研藥物實現了 2 型糖尿病成人患者糖化血紅蛋白平均 1.3% 至 1.6% 的降幅，且在用藥四周內就可觀察到改善，同時，高劑量組在第 40 周時實現平均體重減輕 7.3kg。禮來表示，預計將在今年年底前向全球監管機構提交 orforglipron 用於體重管理的上市申請，預計於 2026 年提交其用於治療 2 型糖尿病的上市申請。
Source: 智通財經 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.